Prostate Cancer Screening in African-American Men

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Experts weigh in on the practical applications of PSMA PET imaging

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Results from a retrospective study show that 177Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.